Lubrizol Corporation and Polyhose India have jointly inaugurated a new precision medical tubing manufacturing facility in Chennai, Tamil Nadu, marking a significant milestone for India’s rubber and medical device sectors. The Lubrizol Polyhose medical tubing plant will produce minimally invasive medical devices including precision extruded catheters, drainage tubes, and surgical tubing for both domestic and export markets, capitalising on India’s rapidly growing medical technology industry.
The Chennai facility represents one of the first large-scale collaborations between a global specialty chemicals leader (Lubrizol, headquartered in Wickliffe, Ohio) and an Indian rubber tubing specialist (Polyhose, based in Chennai) to manufacture high-specification medical-grade rubber and thermoplastic elastomer (TPE) tubing in India. The move aligns with India’s push to become a global medical device manufacturing hub under the Production-Linked Incentive (PLI) scheme for medical devices.
What Will the Lubrizol-Polyhose Chennai Plant Manufacture?
The Chennai plant specialises in precision extruded medical tubing for minimally invasive procedures—catheters for cardiovascular interventions, drainage and infusion tubes for critical care, and multi-lumen tubing for complex surgical devices. Lubrizol contributes its Tecoflex, Tecothane, and Pellethane medical-grade thermoplastic polyurethane (TPU) and TPE compounds, which meet US FDA 21 CFR and ISO 10993 biocompatibility standards. Polyhose brings its 25-year expertise in high-precision rubber and polymer extrusion for industrial and automotive applications, now being applied to the more demanding tolerances required for medical-grade tubing. The facility is designed to serve device original equipment manufacturers (OEMs) across India, the US, Germany, and Japan, where demand for minimally invasive surgical tools is growing at 9–11% annually.
Why Is India Emerging as a Medical Rubber Manufacturing Destination?
India’s medical device market is projected to grow from $12 billion in 2026 to $50 billion by 2030, making it one of the fastest-growing segments globally. The government’s PLI scheme for medical devices, which offers 5% incentive on incremental sales for four years, has attracted Rs. 2,420 crore in committed investment from 26 companies. Chennai has emerged as a preferred location due to its established rubber processing industry, port access for exports, proximity to Tamil Nadu’s strong healthcare infrastructure, and the state government’s proactive investment policies. The Lubrizol-Polyhose partnership is the latest in a series of investments that include B. Braun, Fresenius, and Cardinal Health establishing manufacturing or sourcing operations in Tamil Nadu for medical rubber and polymer components.
Market Reaction and Industry Response
The inauguration has been welcomed by the All India Rubber Industries Association (AIRIA) as evidence that India’s rubber sector is successfully diversifying beyond its traditional automotive and industrial segments into high-value medical applications, where margins are substantially higher. Medical-grade tubing commands prices 8–15 times higher per kilogram than equivalent industrial rubber tubing, making the segment transformative for rubber manufacturers willing to invest in cleanroom manufacturing and quality certifications. Polyhose’s move into medical manufacturing mirrors strategies pursued by other Indian rubber companies including Mantaline India and Elastomers & Allied Products, which have expanded into pharmaceutical and medical device tubing over the past three years.
What Happens Next for India’s Medical Rubber Sector?
The Lubrizol-Polyhose plant is targeting ISO 13485 medical device quality certification by Q4 2026, which will open export markets in the European Union and the United States. India’s broader medical rubber tubing sector is expected to register 14% CAGR through 2030, driven by rising domestic surgical volumes, government hospital infrastructure expansion under Ayushman Bharat, and the China+1 diversification strategy adopted by global medical OEMs. The rubber industry’s presence at TechnoBiz Rubber Week 2026 in Bengaluru (July 29–31) will feature a dedicated session on medical and pharmaceutical rubber applications, reflecting the sector’s growing strategic importance.
Frequently Asked Questions
What products will the Lubrizol-Polyhose Chennai plant produce?
The Chennai facility will manufacture precision extruded medical tubing for minimally invasive procedures, including cardiovascular catheters, drainage and infusion tubes, and multi-lumen surgical tubing. Products use Lubrizol’s medical-grade TPU and TPE compounds meeting FDA 21 CFR and ISO 10993 biocompatibility standards.
How does this fit into India’s medical device manufacturing ambitions?
India’s medical device market is projected to reach $50 billion by 2030, and the PLI scheme for medical devices has attracted Rs. 2,420 crore in committed investments. The Lubrizol-Polyhose collaboration exemplifies how Indian rubber manufacturers are partnering with global materials companies to move up the value chain into high-margin medical applications.
What is the significance of Chennai as a medical rubber manufacturing location?
Chennai offers a unique combination of established rubber processing expertise, port infrastructure for exports, proximity to Tamil Nadu’s healthcare cluster, and state government incentives. It has attracted investments from B. Braun, Fresenius, and Cardinal Health, creating an emerging medical manufacturing ecosystem that supports the Lubrizol-Polyhose facility’s supply chain needs.
Leave a comment